phase I clinical study
Effector Therapeutics Begins Expansion Cohorts in Zotatifin Trial for Biomarker-Defined Tumors
The firm will open cancer-specific cohorts of HR-positive breast cancer and KRAS-mutated NSCLC patients as a next step in its ongoing Phase I/II clinical trial.
Ambrx Begins Phase I Trial of ARX517 in PSMA-Expressing Tumors
The Phase I dose escalation and dose expansion study is enrolling up to 76 patients with PSMA-expressing solid tumors.
SpringWorks, MSK Collaborate to Study MEK Inhibitor in Certain Solid TumorsÂ
The partners will explore the activity of mirdametinib with fulvestrant in breast cancer patients with MAPK alterations and as a single agent in other MAPK-altered solid tumors.
Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib
The NGS firm will work with Impact to develop companion diagnostics to select patients eligible for Impact's synthetic lethality drugs, beginning with senaparib.
T-knife Therapeutics Raises $110M in Series B Financing to Advance TCR Treatments
The firm will begin enrolling MAGE-A1-positive solid cancer patients to a Phase I/II clinical trial of its autologous TCR therapy TK-8001 later this year.